Change in Directors' and PDMR interests in the shares of Acacia Pharma Group plc
ACACIA PHARMA GROUP PLC
Change in Directors' and PDMR interests in the shares of Acacia Pharma Group plc
Cambridge, UK and Indianapolis, US –19 July 2019: Acacia Pharma Group plc (“Acacia Pharma”, the "Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces the following awards under the Company’s share plans;
This notification is made in accordance with the Company's obligations under the Market Abuse Regulation.
The following transactions have taken place in relation to the Executive Directors and PDMR’s under the Company's share plans as well as certain Non-Executive Directors.
The awards reflect the voluntary foregoing of certain contractual rights to salary and other benefits given the need to preserve cash resources within the Group. Furthermore, as noted in the 2018 Annual Report, the annual award of share incentives was delayed pending determination of the status of the BARHEMSYS® NDA, the timing and details of which were set out in a press release dated 8 July 2019.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Michael Bolinder | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Incoming Chief Executive Officer and director/PDMR | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 75,000 | £0 | ||
| Note 2 | £0 | 175,000 | £0 | ||
| Note 3 | £0 | 100,000 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 350,000 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Julian Gilbert | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Outgoing Chief Executive Officer and director/PDMR | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 4 | £0 | 150,000 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 150,000 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Christine Soden | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Chief Financial Officer and Director/PDMR | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 70,000 | £0 | ||
| Note 2 | £0 | 50,000 | £0 | ||
| Note 3 | £0 | 75,000 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 195,000 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Gabriel Fox | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | PDMR | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 50,000 | £0 | ||
| Note 2 | £0 | 45,000 | £0 | ||
| Note 3 | £0 | 70,000 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 165,000 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Patrick Vink | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Director | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 16,770 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 16,770 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | John Brown | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Director | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 7,290 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 7,290 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) | Name | Edward Borkowski | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Director | |||
| b) | Initial notification/ Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Acacia Pharma Group plc | |||
| b) | LEI | 213800SLDKXWKT6E3381 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of £0.02 each GB00BYWF9Y76 | |||
| b) | Nature of the transaction | Grant of conditional awards under the Company’s Performance Share Plan | |||
| c) | Price(s) and volume(s) | Price | Volume (s) | Total | |
| Note 1 | £0 | 6,855 | £0 | ||
| d) | Aggregated information - Aggregated volume - Price | 6,855 £0 | |||
| e) | Date of the transaction | 18 July 2018 | |||
| f) | Place of the transaction | Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a) |
By: Nasdaq / GlobeNewswire
- 19 Jul 2019
Back to overview
Enhance your business development with Biotechgate
| ||||